SEC Filing Document

Company: Ambitious Entertainment, Inc.
Ticker: 
CIK: 1900851
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023581
Exchange: 
SIC Code: 7812
SIC Description: Services-Motion Picture & Video Tape Production
URL: https://www.sec.gov/Archives/edgar/data/1900851/000149315226023581/forms-1.htm

Chunk 8 of 57
Word Count: 1364
Character Count: 8598

Document Content:

(the “PCAOB”) requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about the audit and the financial statements of the issuer; ● provide certain disclosure regarding executive compensation required of larger public companies or hold stockholder advisory votes on the executive compensation required by the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), ● obtain stockholder approval of any golden parachute payments not previously approved. will cease to be an emerging growth company upon the earliest of the following: ● the last day of the fiscal year in which we have $1.235 billion or more in total annual gross revenues; ● the date on which we become a “large accelerated filer” (the fiscal year-end on which the total market value of our common equity securities held by non-affiliates is $700 million or more);

●	the
date on which we issue more than $1.0 billion of non-convertible debt over a three-year period, or

●	the
last day of the fiscal year following the fifth anniversary of our initial public offering.

have elected to take advantage of certain of the reduced disclosure obligations in this prospectus, and may elect to take advantage of
other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
from what you might receive from other public reporting companies.

addition, “emerging growth company” may take advantage of the extended transition period provided in Section 7(a)(2)(B) of
the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can
delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

Implications
of Being a Smaller Reporting Company

are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30; or (ii) our annual revenues did
not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure obligations,
it may also make comparison of our financial statements with other public companies difficult or impossible.

Corporate
Information

Our
principal executive offices are located at 112 W 6th Avenue, Vancouver, British Columbia V5Y 1K6, Canada.
Our telephone number is (604) 218-3374. The address of our website is www.ambitious.tv. The inclusion of our website address in
this prospectus does not include or incorporate by reference the information on our website into this prospectus.

The
Offering

The
following is a summary of certain terms of this offering.

Securities
offered by us: 3,555,556
shares of common stock, par value $0.001 per
share.

Initial
public offering price: $4.50
per share, the midpoint of the estimated initial public offering price range set forth on the cover of this prospectus.

Number
of shares outstanding before the offering (1): 15,712,900
shares of common stock and 367,341 shares of Series A preferred stock, par value $0.0001 per share.

Number
of shares outstanding after the offering (1): 19,268,456
shares of common stock and 367,341 shares of Series A preferred stock, par value $0.0001 per share.

Overallotment
option: We
have granted the underwriters an option exercisable in whole or in part and from time to time for a period of up to 45 days
from the date of this prospectus to purchase from us up to an additional 533,333 shares of our common stock at the initial
public offering price per share, less underwriting discounts and commissions, solely to cover over-allotments, if any.

Use
of proceeds: We
estimate that we will receive net proceeds of approximately $[●] million, assuming an initial public offering price of $[●]
per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the underwriting discounts
and commissions and estimated offering expenses payable by us.

Although
we have not yet determined with certainty the manner in which we will allocate the net proceeds of this offering, we expect
to use the net proceeds from this offering for working capital, offering expenses, and other general corporate purposes. We
may also use a portion of the proceeds from this offering to acquire or invest in additional intellectual property and to expand
our development pipeline. We have not allocated specific amounts of net proceeds for any of these purposes. See “Use of
Proceeds”.

Risk
factors: An
investment in our securities involves a high degree of risk. See “Risk Factors” beginning on page 15 of this prospectus
and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to
invest in shares of our common stock.

Lock-up: We
and our directors, officers and certain of our stockholders have agreed not to offer for sale, issue, sell, contract to sell, pledge
or otherwise dispose of any shares of our common stock or securities convertible into or exercisable for shares of our common stock
for a period of 180 days after the date of this prospectus. See “Underwriting”.

Representative’s
Warrants: We
have agreed to issue to the representative of the underwriters or its designees at the closing of this offering, warrants to purchase
the number of shares of our common stock equal to 5% of the aggregate number of shares sold in this offering, including any
shares of our common stock sold pursuant to the underwriters’ over-allotment option (the “Representative’s Warrants”).
The Representative’s Warrants will be exercisable at any time and from time to time, in whole or in part, during the four-and-a-half-year
period commencing six months after the commencement of sales in this offering. The exercise price of the Representative’s Warrants
will equal 125% of the initial public offering price per share, subject to adjustments. See “Underwriting”.

NYSE
Trading Symbol: We
intend to apply have the shares of our common stock offered hereby listed on the NYSE American under the symbol “___”.
No assurance can be given that our application will be approved. We will not proceed with this offering in the event shares of our
common stock are not approved for listing on the NYSE American.

(1)	The
number of shares that will be outstanding after this offering is based on 15,712,900 shares of common stock outstanding as
of April 1, 2026, but excludes:

●	130,000 shares of our common stock issuable upon the
conversion of the Bridge Financing warrants with a weighted average conversion price of $4.50 per share.

shares of our common stock issuable upon the conversion of convertible notes with a weighted average
conversion price of $2.25 per share.

shares of our common stock issuable upon the conversion of Series A warrants with a weighted average conversion price of $2.25 per share.

shares of our common stock issuable upon the exercise of Series B and C warrants with a weighted average conversion price of $2.48 per share.

exercise by the underwriters of the over-allotment option.

exercise of any Representative’s Warrants.

RISK
FACTORS

investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and all other
information contained in this prospectus before deciding whether to invest in our common stock. If any of the following risks are realized,
our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price
of the shares of our common stock could decline, and you could lose all or part of your investment. Some statements in this prospectus,
including such statements in the following risk factors, constitute forward-looking statements. See the section entitled “Special
Note Regarding Forward-Looking Statements”.

Risks
Related to Our Company

Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, and we
may not be able to continue operations without additional financing.